Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Lang, Jianshe ^a   Yang, Ning ^a   Deng, Jiejie ^a   Liu, Kangtai ^a   Yang, Peng ^a   Zhang, Guigen ^a   Jiang, Chengyu ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; HEPARIN; HEPARIN LYASE; LACTOFERRIN; PROTEOHEPARAN SULFATE;

ARTICLE; BINDING SITE; CELL STRAIN HEK293; CONTROLLED STUDY; DOSE RESPONSE; HOST CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKOCYTE ADHERENCE; LEUKOCYTE AGGREGATION; NATURAL KILLER CELL; NEUTROPHIL; PROTEIN BINDING; PROTEIN LOCALIZATION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TEMPERATURE; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS PATHOGENESIS; CELL LINE; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

SARS CORONAVIRUS;

CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LACTOFERRIN; PROTEIN BINDING; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS INTERNALIZATION;

EID: 80051922480     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023710     Document Type: Article

References (59)

1. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, et al. (2003) Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302: 276-278.
2. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, et al. (2003) Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362: 263-270.
3. Hofmann H, Pohlmann S, (2004) Cellular entry of the SARS coronavirus. Trends in Microbiology 12: 466-472.
4. Bartlam M, Yang H, Rao Z, (2005) Structural insights into SARS coronavirus proteins. Current Opinion in Structural Biology 15: 664-672.
5. Li F, Li W, Farzan M, Harrison SC, (2005) Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor. Science 309: 1864-1868.
6. Du L, He Y, Zhou Y, Liu S, Zheng B, Jiang S, (2009) The Spike protein of SARS-CoV- a target for vaccine and therapeutic development. Nature review Microbiology 7: 226-236.
7. Chen J, Subbarao K, (2007) The Immunobiology of SARS. Annu Rev Immunol 25: 443-472.
8. Reghunathan R, Jayapal M, Hsu L, Chng H, Tai D, et al. (2005) Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. BMC Immunology 6: 2.
9. Farnaud S, Evans RW, (2003) Lactoferrin-a multifunctional protein with antimicrobial properties. Molecular Immunology 40: 395-405.
10. Waartsa BL, Anekea JC, Smita JM, Kimatac K, Bittmand R, et al. (2005) Antiviral activity of human lactoferrin: Inhibition of alphavirus interaction with heparan sulfate. Virology 333: 284-292.
11. Andersen JH, Osbakk SA, Vorland LH, Traavik T, Gutteberg TJ, (2001) Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Research 51: 141-149.
12. Beljaars L, Strate WA, Bakker HI, Smit CR, Weemaes AL, et al. (2004) Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. Antiviral Research 63: 197-208.
13. Marchetti M, Trybala E, Superti F, Johansson M, Bergstrom T, (2004) Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology 318: 405-413.
14. Waartsa BL, Anekea OJ, Smita JM, Kimatac K, Bittmand R, et al. (2005) Antiviral activity of human lactoferrin: Inhibition of alphavirus interaction with heparan sulfate. Virology 333: 284-292.
15. Longhi G, Pietropaolo V, Mischitelli M, Longhi C, Conte MP, et al. (2006) Lactoferrin inhibits early steps of human BK polyomavirus infection. Antiviral Research 72: 145-152.
16. Drobni P, Naslund J, Evander M, (2004) Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Research 64: 63-68.
17. Ammendolia MG, Pietrantoni A, Tinari A, Valenti P, Superti F, (2007) Bovine lactoferrin inhibits echovirus endocytic pathway by interacting with viral structural polypeptides. Antiviral Research 73: 151-160.
18. Puddua P, Borghi P, Gessani S, Valenti P, Belardelli F, et al. (1998) Antiviral effect of bovine lactoferrin saturated with metalions on early steps of human immunodeciency virus type 1 infection. The International Journal of Biochemistry & Cell Biology 30: 1055-1063.
19. Superti F, Siciliano R, Rega B, Giansanti F, Valenti P, et al. (2001) Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection. Biochimica Biophysica Acta 1528: 107-115.
20. Belting M, (2003) Heparan sulfate proteoglycan as a plasma membrane carrier. Trends in biochemical sciences 28: 145-151.
21. Jenssen H, Hancock EW, (2009) Antimicrobial properties of lactoferrin. Biochimie 91: 19-29.
22. Wang H, Yang P, Liu K, Guo F, Zhang Y, et al. (2008) SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Research 18: 290-301.
23. Kuba K, Imai Y, Rao S, Gao H, Guo F, et al. (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11: 875-879.
24. Nègre D, Mangeot PE, Duisit G, Blanchard S, Vidalain PO, et al. (2000) Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther 7: 1613-1623.
25. Watanabe R, Matsuyama S, Shirato K, Maejima M, Fukushi S, et al. (2008) Entry from the cell surface of severe acute respiratory syndrome coronavirus with cleaved S protein as revealed by pseudotype virus bearing cleaved S protein. J Virol 82: 11985-11991.
26. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, et al. (2004) Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A 101: 4240-4245.
27. González CS, Arévalo GS, Rascón CQ, (2009) Lactoferrin: structure, function and applications. Int J Antimicrob Agents 33: 1-8.
28. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, et al. (2005) Tumor necrosis factor convertase (ADAM17) mediates regulated ectodomain shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) receptor Angiotensin-converting Enzyme-2 (ACE2). The Journal of Biological Chemistry 280: 30113-30119.
29. Krahling V, Stein DA, Spiegel M, Weber F, Muhlberger E, (2009) Severe Acute Respiratory Syndrome Coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity. J Virol 83: 2298-2309.
30. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, et al. (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450-454.
31. Han DP, Lohani M, Cho MW, (2007) Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. J Virol 81: 12029-12039.
32. Yamauchi K, Wakabayashi H, Shin K, Takase M, (2006) Bovine lactoferrin: benefits and mechanism of action against infections. Biochem Cell Biol 84: 291-296.
33. Zautner AE, Korner U, Henke A, Badorff C, Schmidtke M, (2003) Heparan sulfates and Coxsackievirus-Adenovirus receptor: each one mediates Coxsackievirus B3 PD infection. J Virol 77: 10071-10077.
34. Selinka HC, Florin L, Patel HD, Freitag K, Schmidtke M, et al. (2007) Inhibition of transfer to secondary receptors by Heparan Sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol 81: 10970-10980.
35. Leistner CM, Bernhard SG, Glebe D, (2008) Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cellular Microbiology 10: 122-133.
36. Vicenzi E, Canducci F, Pinna D, Mancini N, Carletti S, et al. (2004) Coronaviridae and SARS-associated coronavirus strain HSR1. Emerging Infectious Diseases 10: 413-418.
37. Liu J, Thorp SC, (2002) Cell surface heparan sulfate and its roles in assisting viral infections. Med Res Rev 22: 1-25.
38. Baba M, Snoeck R, Pauwels R, Clercq E, (1988) Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 32: 1742-1745.
39. Arai T, Matsumoto K, Saitoh K, Ui M, Ito T, et al. (1998) A New System for Stringent, High-Titer Vesicular Stomatitis Virus G Protein-Pseudotyped Retrovirus Vector Induction by Introduction of Cre Recombinase into Stable Prepackaging Cell Lines. J Virol 72: 1115-1121.
40. Conti C, Mastromarino P, Riccioli A, Orsi N, (1991) Electrostatic interactions in the early events of VSV infection. Research in Virology 142: 17-24.
41. Copreni E, Castellani S, Palmieri L, Penzo M, Conese M, (2008) Involvement of glycosaminoglycans in vesicular stomatitis virus G glycoprotein pseudotyped lentiviral vector-mediated gene transfer into airway epithelial cells. J Gene Med 10: 1294-302.
42. Strate BW, Beljaars L, Harmsen GM, Meijer DK, (2001) Antiviral activities of lactoferrin. Antiviral Research 52: 225-239.
43. Spear PG, (2004) Herpes simplex virus: receptors and ligands for cell entry. Cellular Microbiology 6: 401-410.
44. Sapp M, Haba MB, (2009) Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS Journal 276: 7206-7216.
45. Leistner CM, Bernhard SG, Glebe D, (2008) Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cellular Microbiology 10: 122-133.
46. Akhtar J, Shukla D, (2009) Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS Journal 276: 7228-7236.
47. Cocquerel L, Voisset C, Dubuisson J, (2006) Hepatitis C virus entry: potential receptors and their biological functions. Journal of General Virology 87: 1075-1084.
48. Burckhardt CJ, Greber UF, (2009) Virus Movements on the Plasma Membrane Support Infection and Transmission between Cells. PLoS Pathogens 5: e1000621.
49. Selinka HC, Giroglou T, Sapp M, (2002) Analysis of the Infectious Entry Pathway of Human Papillomavirus Type 33 Pseudovirions. Virology 299: 279-287.
50. Schulze A, Gripon P, Urban S, (2007) Hepatitis B Virus Infection Initiates With a Large Surface Protein-Dependent Binding to Heparan Sulfate Proteoglycans. Hepatology 46: 1759-1768.
51. Vivès RR, Jacob HL, Fender P, (2006) Heparan Sulphate Proteoglycans and Viral Vectors: Ally or Foe? Current Gene Therapy 6: 35-44.
52. Haan CA, Li Z, Lintelo E, Bosch BJ, Haijema BJ, et al. (2005) Murine coronavirus with an extended host range uses heparan sulfate as an entry receptor. J Virol 79: 14451-14456.
53. Groot F, Geijtenbeek TB, Sanders RW, Baldwin CE, Hernandez MS, et al. (2005) Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN-gp120 interaction. J Virol 79: 3009-3015.
54. Baker EN, Baker HM, (2009) A structural framework for understanding the multifunctional character of lactoferrin. Biochimie 91: 3-10.
55. Jenssen H, (2005) Anti herpes simplex virus activity of lactoferrin/lactoferricin- an example of antiviral activity of antimicrobial protein/peptide. Cell Mol Life Sci 62: 3002-3013.
56. Valenti P, Antonini G, (2005) Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci 62: 2576-2587.
57. Baker EN, Baker HM, (2005) Molecular structure, binding properties and dynamics of lactoferrin. Cell Mol Life Sci 62: 2531-2539.
58. Thorne RG, Lakkaraju A, Boulan ER, Nicholson C, (2008) In vivo diffusion of lactoferrin in brain extracellular space is regulated by interactions with heparan sulfate. Proc Natl Acad Sci U S A 105: 8416-8421.
59. Yeung KS, Yamanaka GA, Meanwell NA, (2006) Severe Acute Respiratory Syndrome Coronavirus entry into host cells: opportunities for therapeutic intervention. Medicinal Research Reviews 26: 414-433.